The exact pathogenesis of arthritis in children or adults is not known, but several cells contribute to the development of autoimmune arthritis including T and B lymphocytes, synovial cells, macrophages, neutrophils and osteoclasts (OC) [1-3]. Identifying common signaling molecules affecting the osteo-immune system and their impact on normal and pathological bone loss may lay the groundwork for future therapies for the variety of diseases such as rheumatoid arthritis. We have found PLC32 to be such candidate. In addition to defective B cell development, PLC32-/- mice are osteopetrotic due to aberrant osteoclast recruitment and function [4] [5]. PLC32 affects the two major RANKL-induced signaling pathways during osteoclastogenesis, namely NF:B and NFAT activation, as well as activation and proper localization of 1v23 integrin adhesive structure in the resorbing cell. Unexpectedly, we also found that PLC32 -/- mice are protected from the insurgence of inflammation associated with two different models of arthritis, the serum induced arthritis which is strictly dependent on neutrophils [6], and the antigen induced arthritis which relays on T cell activation. Although PLC32 is not expressed in T cells, PLC32 controls the ability of dendritic cells (DC) to activate T cells. Antigen pulsed PLC32-/- DC, but not WT DC, fail to initiate an inflammatory reaction when injected into WT mice following a local knee injection of the antigen. Conversely, injection of antigen pulsed WT DC into PLC32-/- mice completely restores the inflammatory response without eliciting osteoclast recruitment and focal osteolysis. These intriguing data position PLC32 as a critical modulator of bone integrity and immune responses during inflammatory arthritis. Based on this observation, we hypothesize that PLC32 is required for DC-mediated T cell activation during inflammatory arthritis. Thus, we aim to study the role of PLC32 in antigen presentation and in DC motility during inflammatory arthritis. We believe that expanding the focus of our original proposal from understanding the role of PLC32 in the OCs to study its effects in DC, may lead to new therapeutic avenues aimed at targeting the inflammatory and osteolytic components of rheumatoid arthritis. This application is in response to Notice NOT-OD-09-058: NIH Announces the Availability of Recovery Act Funds for Competitive Revision.

Public Health Relevance

The overall goal of this proposal is to expand the goals of our original R01 proposal from studying PLC32- mediated regulation of osteoclast differentiation and function to examining the role of PLC32 in DC-mediated T cell activation. Specifically, we aim to investigate the role of PLC32 in antigen presentation and in the recruitment of DCs to the lymph nodes, both critical events required for T cell activation, during inflammatory arthritis. Since the interaction between immune cells and osteoclast is increasingly recognized, identifying common signaling molecules affecting the osteo-immune system and their impact on normal and pathological bone loss may lay the groundwork for future therapies for the variety of diseases such as inflammatory arthritis. .

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
3R01AR053628-04S1
Application #
7810845
Study Section
Special Emphasis Panel (ZRG1-MOSS-A (96))
Program Officer
Sharrock, William J
Project Start
2009-09-25
Project End
2010-09-24
Budget Start
2009-09-25
Budget End
2010-09-24
Support Year
4
Fiscal Year
2009
Total Cost
$174,400
Indirect Cost
Name
Washington University
Department
Orthopedics
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
D'Amico, Lucia; Mahajan, Sahil; Capietto, Aude-Hélène et al. (2016) Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer. J Exp Med 213:827-40
Capietto, Aude-Hélène; Chan, Szeman Ruby; Ricci, Biancamaria et al. (2016) Novel ER? positive breast cancer model with estrogen independent growth in the bone microenvironment. Oncotarget 7:49751-49764
Mori, Giorgio; D'Amelio, Patrizia; Faccio, Roberta et al. (2015) Bone-immune cell crosstalk: bone diseases. J Immunol Res 2015:108451
Decker, Corinne E; Yang, Zhengfeng; Rimer, Ryan et al. (2015) Tmem178 acts in a novel negative feedback loop targeting NFATc1 to regulate bone mass. Proc Natl Acad Sci U S A 112:15654-9
Zeng, Rong; Faccio, Roberta; Novack, Deborah V (2015) Alternative NF-?B Regulates RANKL-Induced Osteoclast Differentiation and Mitochondrial Biogenesis via Independent Mechanisms. J Bone Miner Res 30:2287-99
Zamani, Ali; Decker, Corinne; Cremasco, Viviana et al. (2015) Diacylglycerol Kinase ? (DGK?) Is a Critical Regulator of Bone Homeostasis Via Modulation of c-Fos Levels in Osteoclasts. J Bone Miner Res 30:1852-63
Yang, Chang; Davis, Jennifer L; Zeng, Rong et al. (2013) Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation. Cancer Discov 3:212-23
Decker, Corinne; Hesker, Pamela; Zhang, Kaihua et al. (2013) Targeted inhibition of phospholipase C ?2 adaptor function blocks osteoclastogenesis and protects from pathological osteolysis. J Biol Chem 288:33634-41
Capietto, Aude-Hélène; Kim, Seokho; Sanford, Dominic E et al. (2013) Down-regulation of PLC?2-?-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer. J Exp Med 210:2257-71
Cremasco, Viviana; Decker, Corinne E; Stumpo, Deborah et al. (2012) Protein kinase C-delta deficiency perturbs bone homeostasis by selective uncoupling of cathepsin K secretion and ruffled border formation in osteoclasts. J Bone Miner Res 27:2452-63

Showing the most recent 10 out of 14 publications